Effect of Lenalidomide (R) +/- Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies

Subjects

Subjects :

multiple myeloma
newly diagnosed multiple myeloma
MM
daratumumab
lenalidomide discontinuation

Details

Language :

English

Database :

OpenAIRE

Journal :

Moreau, P, Facon, T, Usmani, S Z, Dimopoulos, M, Kumar, S, Plesner, T, Goldschmidt, H, Reece, D, Orlowski, R Z, Perrot, A, Leiba, M, Chari, A, San-Miguel, J, Cook, G, Iida, S, Pei, H, Van Rampelbergh, R, Uhlar, C M, Renaud, T, Ukropec, J, Kobos, R & Bahlis, N 2020, ' Effect of Lenalidomide (R) +/-Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies ', Clinical Lymphoma, Myeloma & Leukemia, vol. 20, no. 1 supplement, MM-339, pp. S306-S307 . https://doi.org/10.1016/S2152-2650(20)30491-2, Web of Science

Accession number :

edsair.dedup.wf.001..e4417de72ccfe8f55a51bcc06f0a00ff

Full Text :

https://doi.org/10.1016/S2152-2650(20)30491-2